Skip to main content

Articles

Payers' Guide, FDA Approvals

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Payers' Guide, FDA Approvals

Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation

Payers' Guide, FDA Approvals

Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease

Payers' Guide, FDA Approvals

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Lung Cancer, Payers' Guide, FDA Approvals, Oncology

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Payers' Guide, FDA Approvals

Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma

Payers' Guide, FDA Approvals

Aliqopa (Copanlisib), an Intravenous PI3K Inhibitor, Approved for Patients with Relapsed Follicular Lymphoma

Payers' Guide, FDA Approvals

Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis

Payers' Guide, FDA Approvals

Xadago (Safinamide), an Oral MAO-B Inhibitor, FDA Approved as Adjunctive Treatment for Patients with Parkinson’s Disease

Payers' Guide, FDA Approvals

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Page 73 of 244
Results 721 - 730 of 2434